Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [(223)Ra]RaCl(2) therapy

[(223)Ra]RaCl(2) dichloride treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) is associated with improved overall survival (OS) and a delay in the time to the first symptomatic skeletal-related event. The aim of this study was to evaluate the quality of life (QoL) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sraieb, Miriam, Hirmas, Nader, Conrad, Rupert, Marinova, Milka, Essler, Markus, Herrmann, Ken, Ahmadzadehfar, Hojjat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505355/
https://www.ncbi.nlm.nih.gov/pubmed/32957385
http://dx.doi.org/10.1097/MD.0000000000022287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505355/
https://www.ncbi.nlm.nih.gov/pubmed/32957385
http://dx.doi.org/10.1097/MD.0000000000022287

Ejemplares similares